EN DE
STOCK COMPARISON

Eli Lilly and vs Pfizer: Fair Value & Quality

Both stocks run through our valuation models. Here is how Eli Lilly and (LLY) and Pfizer (PFE) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Pfizer as the less overvalued of the two: Eli Lilly and trades at $1,160 versus a fair value of $389 (-66%), while Pfizer trades at $28.81 versus $24.87 (-14%).
Eli Lilly and
LLY · USD · Health Care
-66%
upside to fair value
overvalued
Price$1,160
Fair Value$389
Quality69/100
Pfizer
PFE · USD · Health Care
-14%
upside to fair value
overvalued
Price$28.81
Fair Value$24.87
Quality61/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Eli Lilly andPfizer
Valuation
42.2×P/E (TTM)18.7×
14.67×P/S (TTM)2.18×
39.94×P/B1.60×
30.2×EV/EBITDA7.8×
1.54×PEG2.86×
−66.4%Fair value upside−13.7%
0.5%Dividend yield6.0%
$6.23Dividend per share$1.72
Profitability
49%Operating margin32%
1.42×EBIT margin trend (5Y)1.13×
107%Return on equity8%
21%Return on assets6%
Growth
56%Revenue growth (YoY)5%
31.7%Avg. growth/yr (3Y)-14.6%
21.6%Avg. growth/yr (5Y)8.5%
+29.3%Value creation/yr−7.8%
Balance & size
37.3×Interest coverage (EBIT/interest)5.8×
1.54×Debt / equity0.70×
$1.1TMarket cap$138B
mixedGrowth qualityweak

Eli Lilly and leads: 9 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Eli Lilly andof which business quality 65 · market factors 78 Pfizerof which business quality 58 · market factors 71
ProfitabilityMargins and returns on capital today
85
37
Quality GrowthAre margins and returns improving?
86
43
CashflowEarnings quality: real cash, not paper profit
51
68
Fin. StrengthBalance sheet, leverage, solvency risk
53
42
InvestmentDisciplined investing over empire-building
15
93
Low VolatilityCalm price path (market factor)
77
91
MomentumPrice trend over the last 3–12 months (market factor)
71
54
52W MomentumDistance to the 52-week high (market factor)
92
79
Net IssuanceBuybacks instead of dilution
93
84

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyEli Lilly andPrice $1,160PfizerPrice $28.81
DCF Models-71%below the price$334-29%below the price$20.36
Earnings-Based-79%below the price$239-42%below the price$16.62
Dividend Discount-90%below the price$115-5%close to the price$27.46
Multiples-69%below the price$358-8%close to the price$26.59
Asset-Based-98%below the price$19.94-65%below the price$10.17
Growth DCF-84%below the price$187-37%below the price$18.17
Economic Profit-70%below the price$347-45%below the price$15.78
Growth Earnings-68%below the price$375-14%close to the price$24.87
Minimum-98%below the price$19.94-65%below the price$10.17
Maximum-68%below the price$375-5%close to the price$27.46
Median-75%below the price$287-33%below the price$19.26
Geometric mean-84%below the price$189-34%below the price$19.13

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Eli Lilly and: 26 of 26 models see the stock below the current price.

Pfizer: 19 of 25 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,160 = current price (white tick)
Pfizer
Bear $17.18Fair Value $24.87Bull $35.71
$28.81 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-66% · bottom 25%

Pfizer · Health Care

Quality score61 · above median
Fair value upside-14% · above median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Pfizer as the less overvalued of the two: Eli Lilly and trades at $1,160 versus a fair value of $389 (-66%), while Pfizer trades at $28.81 versus $24.87 (-14%).

Eli Lilly and has the higher quality score (69/100).

See the full analysis →
Eli Lilly and · Pfizer

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Eli Lilly and

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Pfizer

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.